Sustained improvement of diffuse systemic sclerosis following human cytomegalovirus infection offers insight into pathogenesis and therapy

Rheumatology (United Kingdom)

Volumn 51, Issue 12, 2012, Pages 2296-2298

  Moinzadeh, Pia ^a,b   Khan, Korsa ^a   Ong, Voon H ^a   Denton, Christopher P ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALGANCICLOVIR;

ADULT; ARTIFICIAL VENTILATION; CASE REPORT; COLONOSCOPY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; MIDDLE AGED; MYCOPHENOLIC ACID; REMISSION, SPONTANEOUS; SCLERODERMA, DIFFUSE;

EID: 84870310412     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes137     Document Type: Letter

References (5)

1. Arnson Y, Amital H, Guiducci S et al. The role of infections in the immunopathogensis of systemic sclerosis-evidence from serological studies. Ann N Y Acad Sci 2009;1173:627-32.
2. Lunardi C, Dolcino M, Peterlana D et al. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 2006;3:e2.
3. Radic M, Martinovic Kaliterna D, Radic J. Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis. Neth J Med 2010;68:348-53.
4. Burt RK, Shah SJ, Dill K et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378: 498-506.
5. McSweeney PA, Nash RA, Sullivan KM et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002;100: 1602-10.